Abstract

Since Powell's work in 1966, it has generally been accepted that interfirm links between large drug companies and biotechnology SMEs have a positive impact on the R&D performances of these SMEs. However, a number of recent studies have called this view into question, at least in the French context. The findings of these studies suggest that interfirm links can, to some degree, have a deleterious effect on the intrapreneurial dynamism of small high-tech companies. We met with a number of bio-entrepreneurs to identify the problems created for intrapreneurship by interfirm links, basing our approach on the notion of interfirm intrapreneurship (Antoncic, 2001) and on the idea of the plurality of types of intrapreneurs (Shinn and Lamy, 2006). In effect, not everyone reacts in the same manner to the obstacles standing in the way of their intrapreneurial success. We have focused on two main types of intrapreneurs. Members of the first type focus on relationships characterized by trust and are particularly sensitive to any form of control mechanism; while members of the second type base their approach on a clear division of labour between SMEs and large companies and are relatively favourable to normative constraints.

Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.